9.99
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613 - TipRanks
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
What analysts say about Syndax Pharmaceuticals Inc. stockHigh-octane investment gains - Autocar Professional
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Is Syndax Pharmaceuticals Inc. a good long term investmentFree Capital Efficiency Planning - jammulinksnews.com
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What drives Syndax Pharmaceuticals Inc. stock priceFree Smart Trading Workshop - jammulinksnews.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser
Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser
(SNDX) Trading Advice - news.stocktradersdaily.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade - MarketBeat
UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World
Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser
UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus
How Syndax Pharmaceuticals Inc. stock performs during market volatilityFree Day Trading Recommendations - Newser
UBS Adjusts Price Target on Syndax Pharmaceuticals Inc to $35 From $37, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Syndax (SNDX) While Maintaining Pos - GuruFocus
The Goldman Sachs Group Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):